Furthermore, Listeria-based ANXA2-targeted cancer immunotherapy sensitizes pancreatic ductal adenocarcinoma (PDAC) to treatment with the immune checkpoint inhibitor anti-PD-1 antibody, reshaping the immune microenvironment [133]. This evidence concerns the gene ANXA2 and cancer.